Copyright
©2014 Baishideng Publishing Group Inc.
World J Methodol. Jun 26, 2014; 4(2): 123-132
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.123
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.123
Table 4 Disease-progression-related events used to define secondary end points in randomized trials of metastatic castration-resistant prostate cancer
| Progression event | Trial number | Ref. |
| Clinical | 2 | [26,34] |
| Pain | 2 | [25,35] |
| Skeletal-related events | 4 | [8-10,23] |
| Radiological | 7 | [6,8,9,22,24,25,36] |
| Prostate-specific antigen | 6 | [8-10,24,25,31] |
| Alkaline phosphatase | 2 | [10,31] |
| Mixed | 9 | [7,19,20,21,28,33,37-39] |
- Citation: Colloca G, Venturino A, Governato I. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol 2014; 4(2): 123-132
- URL: https://www.wjgnet.com/2222-0682/full/v4/i2/123.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i2.123